Hypogonadism, Male Clinical Trial
— DVOfficial title:
Validation of Dosing Regimen of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.
Verified date | October 2019 |
Source | Lipocine Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
Status | Completed |
Enrollment | 95 |
Est. completion date | July 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Serum total T below 300 ng/dL based on 2 consecutive blood samples obtained between 6 and 10 AM, on two separate days at approximately the same time of day, following an appropriate washout of current androgen replacement therapy. 2. Subjects should be diagnosed to be primary (congenital or acquired) or secondary hypogonadal (congenital or acquired). 3. Naïve to androgen replacement or has discontinued current treatment and completed adequate washout of prior androgen therapy. Washout must be completed prior to collection of baseline serum T samples to determine study eligibility. Exclusion Criteria: 1. History of significant sensitivity or allergy to androgens, or product excipients. 2. Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up. 3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s). 4. Subjects with symptoms of moderate to severe benign prostatic hyperplasia. 5. Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis 6. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab). 7. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption. 8. History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration. 9. History of stroke or myocardial infarction within the past 5 years. 10. History of or current or suspected prostate or breast cancer. 11. History of untreated and severe obstructive sleep apnea. 12. History of long QT syndrome (QTc > 450) or unexplained sudden death in a first degree relative (parent, sibling, or child). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lipocine Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range | The primary efficacy endpoint and analysis for this study was the percentage of LPCN 1021 treated subjects who had achieved a 24-hour average serum T concentration within the normal range of 300 to 1080 ng/dL at Visit 4, (Day 24 ± 4 days). | Following 24 days of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04467697 -
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
|
Phase 3 | |
Completed |
NCT04326673 -
Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses
|
||
Completed |
NCT03203681 -
Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
|
Phase 4 | |
Completed |
NCT01904734 -
Clomid in Men With Low Testosterone With and Without Prior Treatment
|
Phase 2 | |
Completed |
NCT00398580 -
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00400335 -
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
|
Phase 1 | |
Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
Completed |
NCT03282682 -
Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male
|
N/A | |
Terminated |
NCT03335254 -
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
|
Phase 1/Phase 2 | |
Terminated |
NCT05205837 -
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
|
Phase 4 | |
Completed |
NCT03747003 -
Gonadal Function in Young to Middle Aged HIV-infected Men
|
||
Withdrawn |
NCT03176537 -
Periodontal Profile of Hypogonadic Men
|
Phase 4 | |
Recruiting |
NCT04049331 -
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
|
Phase 2 | |
Completed |
NCT03541395 -
Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males
|
N/A | |
Recruiting |
NCT05249634 -
Testosterone Treatment in Men With Chronic Kidney Disease
|
Phase 2 | |
Not yet recruiting |
NCT05773183 -
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
|
||
Withdrawn |
NCT04717362 -
The Effects of Natesto For Treatment Of Hypogonadism
|
Early Phase 1 | |
Completed |
NCT05806723 -
Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men
|
Phase 4 | |
Completed |
NCT04456296 -
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
|
Phase 4 | |
Not yet recruiting |
NCT06312761 -
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17
|
Phase 1/Phase 2 |